Based on the collective evidence, we propose that apoA-I-based therapies such as CSL112 be tested in patients with FH who have low HDL-cholesterol level or dysfunctional HDL particles, and sub-optimally controlled LDL-cholesterol level despite available therapies. Here, APOA1 is linked to familial hyperaldosteronism.